SE448517B - Farmaceutiskt preparat som paverkar det centrala nervsystemet, innehallande 1,3-dimetyl-5-aminoadamantan och en metylxantinforening - Google Patents

Farmaceutiskt preparat som paverkar det centrala nervsystemet, innehallande 1,3-dimetyl-5-aminoadamantan och en metylxantinforening

Info

Publication number: SE448517B
Authority: SE; Sweden
Prior art keywords: dimethyl; aminoadamantane; compound; nervous system; theophylline
Prior art date: 1978-12-27

Application number

SE7910501A

Other languages

English (en)

Swedish (sv)

Other versions

SE7910501L (sv

Inventor

A Scherm

Original Assignee

Merz & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-12-27

Filing date

1979-12-19

Publication date

1987-03-02

1979-12-19 Application filed by Merz & Co filed Critical Merz & Co

1980-06-28 Publication of SE7910501L publication Critical patent/SE7910501L/

1987-03-02 Publication of SE448517B publication Critical patent/SE448517B/sv

Links

BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 title claims description 27
150000001875 compounds Chemical class 0.000 title claims description 10
210000003169 central nervous system Anatomy 0.000 title claims description 9
239000000825 pharmaceutical preparation Substances 0.000 title 1
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 74
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 56
229960000278 theophylline Drugs 0.000 claims description 37
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 27
229960001948 caffeine Drugs 0.000 claims description 27
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 27
239000000203 mixture Substances 0.000 claims description 25
-1 methylxanthine compound Chemical class 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 18
238000011282 treatment Methods 0.000 claims description 10
206010020651 Hyperkinesia Diseases 0.000 claims description 9
208000000269 Hyperkinesis Diseases 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 8
230000003389 potentiating effect Effects 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
230000000694 effects Effects 0.000 description 23
206010052904 Musculoskeletal stiffness Diseases 0.000 description 21
238000000034 method Methods 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000003814 drug Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
229940079593 drug Drugs 0.000 description 6
239000000126 substance Substances 0.000 description 6
208000009132 Catalepsy Diseases 0.000 description 5
208000018737 Parkinson disease Diseases 0.000 description 5
206010047853 Waxy flexibility Diseases 0.000 description 5
230000003291 dopaminomimetic effect Effects 0.000 description 5
239000012458 free base Substances 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
238000002648 combination therapy Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
238000011160 research Methods 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
238000012360 testing method Methods 0.000 description 4
PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
208000007101 Muscle Cramp Diseases 0.000 description 3
208000005392 Spasm Diseases 0.000 description 3
229930013930 alkaloid Natural products 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
208000015114 central nervous system disease Diseases 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000012154 double-distilled water Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
229960003147 reserpine Drugs 0.000 description 2
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
229950001675 spiperone Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 1
206010001541 Akinesia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010008531 Chills Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 description 1
CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003270 anti-cataleptic effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
229960004046 apomorphine Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
239000003954 decarboxylase inhibitor Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000000686 essence Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000006742 locomotor activity Effects 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
JZKXXXDKRQWDET-UHFFFAOYSA-N meta-tyrosine Natural products OC(=O)C(N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-UHFFFAOYSA-N 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SE7910501A 1978-12-27 1979-12-19 Farmaceutiskt preparat som paverkar det centrala nervsystemet, innehallande 1,3-dimetyl-5-aminoadamantan och en metylxantinforening SE448517B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE2856393A DE2856393C2 (de)	1978-12-27	1978-12-27	Arzneimittel zur Behandlung von Morbus Parkinson

Publications (2)

Publication Number	Publication Date
SE7910501L SE7910501L (sv)	1980-06-28
SE448517B true SE448517B (sv)	1987-03-02

Family

ID=6058522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7910501A SE448517B (sv)	1978-12-27	1979-12-19	Farmaceutiskt preparat som paverkar det centrala nervsystemet, innehallande 1,3-dimetyl-5-aminoadamantan och en metylxantinforening

Country Status (10)

Country	Link
US (1)	US4273774A (fr)
JP (1)	JPS5589219A (fr)
BE (1)	BE880905A (fr)
CA (1)	CA1121726A (fr)
DE (1)	DE2856393C2 (fr)
FR (1)	FR2445145A1 (fr)
GB (1)	GB2044098B (fr)
NL (1)	NL7909307A (fr)
SE (1)	SE448517B (fr)
SG (1)	SG3185G (fr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE33080E (en) *	1981-08-31	1989-10-03	Exxon Research And Engineering Company	Adamantane catalyzed paraffin isomerization
US5506231A (en) *	1989-03-31	1996-04-09	The Children's Medical Center Corporation	Treatment of aids dementia, myelopathy and blindness
US5455279A (en) *	1991-04-19	1995-10-03	The Children's Medical Center Corporation	Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) *	1991-04-04	1997-03-25	Children's Medical Center Corporation	Method of preventing NMDA receptor-mediated neuronal damage
DE19707655A1 (de) *	1997-02-26	1998-08-27	Hoechst Ag	Kombinationspräparat zur Anwendung bei Demenz
US20040122090A1 (en) *	2001-12-07	2004-06-24	Lipton Stuart A.	Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2003274353B2 (en)	2002-10-24	2007-04-05	Merz Pharma Gmbh & Co. Kgaa	Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
MXPA05012493A (es) *	2003-05-27	2006-05-25	Forest Laboratories	Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
JP2006527774A (ja) *	2003-06-16	2006-12-07	アラーガン、インコーポレイテッド	メマンチン経口製剤
US20050113458A1 (en) *	2003-10-22	2005-05-26	Forest Laboratories, Inc.	Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
AR046314A1 (es)	2003-11-05	2005-11-30	Merz Pharma Gmbh & Co Kgaa	Composiciones que comprenden ciclohexilaminas y aminoadamantanos
AU2005204358B2 (en) *	2004-01-05	2008-09-04	Merz Pharma Gmbh & Co. Kgaa	Memantine for the treatment of mild and mild-to-moderate Alzheimer's disease
US7456224B2 (en) *	2004-04-05	2008-11-25	Forest Laboratories Holdings, Ltd.	Method for treating autism
ES2483126T3 (es)	2004-06-17	2014-08-05	Merz Pharma Gmbh & Co. Kgaa	Formulaciones de formas de dosificación de neramexano
JP2008503475A (ja) *	2004-06-17	2008-02-07	フォーレストラボラトリーズ，インコーポレイテッド	メマンチンの放出が改変された製剤
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
TW200616608A (en) *	2004-07-09	2006-06-01	Forest Laboratories	Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
CA2578953A1 (fr) *	2004-09-23	2006-03-30	Merz Pharma Gmbh & Co. Kgaa	Memantine pour le traitement des troubles du comportement de l'enfant
US7619007B2 (en) *	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) *	2004-12-22	2006-09-14	Forest Laboratories, Inc.	1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
JP5666087B2 (ja)	2005-04-06	2015-02-12	アダマス・ファーマシューティカルズ・インコーポレーテッド	Ｃｎｓ関連疾患の治療のための方法及び組成物
EA013474B1 (ru) *	2005-06-16	2010-04-30	Форест Лэборэтериз, Инк.	Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
US20070099947A1 (en) *	2005-11-03	2007-05-03	Alkermes, Inc.	Methods and compositions for the treatment of brain reward system disorders by combination therapy
WO2008005534A2 (fr) *	2006-07-06	2008-01-10	Forest Laboratories, Inc.	Formulations à dissolution orale de mémantine
US7985753B2 (en)	2006-08-04	2011-07-26	Merz Pharma Gmbh & Co. Kgaa	Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators
US20080108643A1 (en) *	2006-11-03	2008-05-08	Forest Laboratories Holdings Limited	Method for treating autism
EP2085398A1 (fr)	2008-02-01	2009-08-05	Merz Pharma GmbH & Co. KGaA	Pyrazolopyrimidines, leur procédé de préparation et leur utilisation en tant que médicament
EP2090576A1 (fr)	2008-02-01	2009-08-19	Merz Pharma GmbH & Co.KGaA	6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
US20090247644A1 (en) *	2008-03-28	2009-10-01	Forest Laboratories Holdings Limited	Memantine formulations
US20110034565A1 (en)	2008-04-18	2011-02-10	University College Dublin, National University Of Ireland, Dublin	Psycho-pharmaceuticals
EP2111858A1 (fr)	2008-04-25	2009-10-28	EPFL Ecole Polytechnique Fédérale de Lausanne	Nouveau traitement pour la maladie d'Alzheimer
US20090275597A1 (en) *	2008-05-02	2009-11-05	Forest Laboratories Holdings Limited	Methods of treating cns disorders
EP2138173A1 (fr)	2008-06-26	2009-12-30	Merz Pharma GmbH & Co.KGaA	Compositions pharmaceutiques comportant des dérivés d'aminoadamantane
TW201116532A (en)	2009-08-05	2011-05-16	Merz Pharma Gmbh & Co Kgaa	Metabotropic glutamate receptor modulators
AU2010325960C1 (en)	2009-12-02	2015-08-06	Adamas Pharma, Llc	Amantadine compositions and methods of use
WO2011127235A1 (fr)	2010-04-07	2011-10-13	Eisai Inc.	Polythérapie pour le traitement de la démence
WO2012052451A1 (fr)	2010-10-18	2012-04-26	Merz Pharma Gmbh & Co. Kgaa	Modulateurs des récepteurs métabotropes au glutamate
JP5848768B2 (ja)	2010-10-29	2016-01-27	ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔＡｔＴｅｌＡｖｉｖＵｎｉｖｅｒｓｉｔｙＬｔｄ．	インドール誘導体及びその製造方法
DK3034079T3 (en)	2010-11-15	2018-02-05	Agenebio Inc	PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
AR084515A1 (es)	2010-12-22	2013-05-22	Merz Pharma Gmbh & Co Kgaa	Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
WO2012085166A1 (fr)	2010-12-22	2012-06-28	Merz Pharma Gmbh & Co. Kgaa	Modulateurs des récepteurs glutamatergiques métabotropes
WO2012152854A1 (fr)	2011-05-12	2012-11-15	Merz Pharma Gmbh & Co. Kgaa	Modulateurs de récepteur de glutamate métabotropique
WO2012172093A1 (fr)	2011-06-17	2012-12-20	Merz Pharma Gmbh & Co. Kgaa	Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate
EP2650284A1 (fr)	2012-04-10	2013-10-16	Merz Pharma GmbH & Co. KGaA	Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique
RU2488388C1 (ru)	2012-05-24	2013-07-27	Ооо "Валента Интеллект"	Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
PL2892540T3 (pl) *	2012-09-06	2018-12-31	Mcpharma Biotech Inc.	Leczenie biegunki i biegunki po odsadzeniu przy pomocy opornej skrobi ziemniaczanej
US10154971B2 (en)	2013-06-17	2018-12-18	Adamas Pharma, Llc	Methods of administering amantadine
CN112409363B (zh)	2013-12-20	2023-11-14	艾吉因生物股份有限公司	用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
EP3102186B1 (fr)	2014-02-04	2021-01-27	Forest Laboratories Holdings Limited	Compositions de donépézil et procédé de traitement de la maladie d'alzheimer
WO2016205739A1 (fr)	2015-06-19	2016-12-22	Belew Mekonnen	Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
SG11201805570WA (en)	2015-12-30	2018-07-30	Corium Int Inc	Systems and methods for long term transdermal administration
WO2017223402A1 (fr)	2016-06-23	2017-12-28	Corium International, Inc.	Matrice adhésive à un domaine hydrophile, un domaine hydrophobes et un agent thérapeutique
US10945968B2 (en)	2016-07-27	2021-03-16	Corium, Inc.	Memantine transdermal delivery systems
CA3031944A1 (fr)	2016-07-27	2018-02-01	Corium International, Inc.	Systemes d'administration transdermique a pharmacocinetique bioequivalent a l'administration orale
AU2017301928B2 (en)	2016-07-27	2023-04-06	Corium, LLC.	Donepezil transdermal delivery system
US11505555B2 (en)	2016-12-19	2022-11-22	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en)	2017-02-09	2019-08-06	Vanderbilt University	Peptide regulators of JNK family kinases
US11173132B2 (en)	2017-12-20	2021-11-16	Corium, Inc.	Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point
BR112020026062B1 (pt)	2018-06-19	2023-04-04	Agenebio, Inc	Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
US20250161238A1 (en)	2022-02-08	2025-05-22	Fikret Sahin	NMDAR Antagonists Prevent Ageing and Aging-Associated Conditions and Diseases Through Increasing 20S Proteasome Activity
US20240132513A1 (en)	2022-08-19	2024-04-25	Agenebio, Inc.	Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3864489A (en) *	1972-03-20	1975-02-04	Gen Foods Corp	Treatment of hyperkinetic conditions with caffeine
CH603545A5 (fr) *	1972-04-20	1978-08-31	Merz & Co
AU6889274A (en) *	1973-05-17	1975-11-20	Astra Laekemedel Ab	Treatment of neurological disorders
DE2518677A1 (de) *	1974-05-06	1975-11-20	Sandoz Ag	Neue pharmazeutische zubereitungen

1978
- 1978-12-27 DE DE2856393A patent/DE2856393C2/de not_active Expired
1979
- 1979-12-19 US US06/105,419 patent/US4273774A/en not_active Expired - Lifetime
- 1979-12-19 SE SE7910501A patent/SE448517B/sv not_active IP Right Cessation
- 1979-12-24 CA CA000342584A patent/CA1121726A/fr not_active Expired
- 1979-12-24 NL NL7909307A patent/NL7909307A/nl not_active Application Discontinuation
- 1979-12-26 FR FR7931664A patent/FR2445145A1/fr active Granted
- 1979-12-27 BE BE0/198784A patent/BE880905A/fr not_active IP Right Cessation
- 1979-12-27 JP JP16955179A patent/JPS5589219A/ja active Pending
- 1979-12-28 GB GB7944464A patent/GB2044098B/en not_active Expired
1985
- 1985-01-11 SG SG31/85A patent/SG3185G/en unknown

Also Published As

Publication number	Publication date
GB2044098B (en)	1983-01-26
US4273774A (en)	1981-06-16
GB2044098A (en)	1980-10-15
SE7910501L (sv)	1980-06-28
FR2445145A1 (fr)	1980-07-25
SG3185G (en)	1985-06-14
JPS5589219A (en)	1980-07-05
CA1121726A (fr)	1982-04-13
DE2856393C2 (de)	1983-04-28
DE2856393A1 (de)	1980-07-03
NL7909307A (nl)	1980-07-01
FR2445145B1 (fr)	1984-10-26
BE880905A (fr)	1980-06-27

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 7910501-1

Effective date: 19920704

Format of ref document f/p: F

Publication	Publication Date	Title
US4273774A (en)	1981-06-16	Central nervous system compositions and method
US4892883A (en)	1990-01-09	Pharmaceutical compositions containing bilobalide for the treatment of neuropathies Ai
WO2000002542A2 (fr)	2000-01-20	Agent a effet antidepressif
CN1255854A (zh)	2000-06-07	1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途
HU215590B (hu)	1999-01-28	Eljárás modafiniltartalmú a nigro-neurostriatalis terület dopaminerg útjára, kolinerg-, noradrenerg- és 5-OH triptamin-neuranokra kifejtett hatás alapján a központi idegrendszer degeneratív megbetegedéseinek kezelésére szolgáló gyógyászati készítmény ..
JPH07509456A (ja)	1995-10-19	２型糖尿病および肥満の治療および予防のための１，３−ジシクロプロピメチル−８−アミノ−キサンチンの使用
DE2423529A1 (de)	1974-12-05	Mittel zur behandlung neurologischer stoerungen
US20140128420A1 (en)	2014-05-08	Nutritional supplement compositions
CZ295801B6 (cs)	2005-11-16	Antitusické přípravky
KR20160130517A (ko)	2016-11-11	혈액학적 장애의 치료에 사용하기 위한 glyt1 억제제
US20060269617A1 (en)	2006-11-30	Supplement compositions and method of use for enhancement of insulin sensitivity
DE69327153T2 (de)	2000-05-25	Anti-hiv-medikament
DE1817843A1 (de)	1972-03-23	Arzneimittel zur Relaxion glatter Muskeln
WO2006132275A1 (fr)	2006-12-14	Agent prophylactique et/ou thérapeutique pour troubles moteurs
CN103622988A (zh)	2014-03-12	虫草素在制备抗抑郁症的药物中的用途及其制备而得的快速抗抑郁症药物
DE69430047T2 (de)	2002-10-17	Pharmazeutische Zusammensetzungen die Isochinolinderivate enthalten
US5434142A (en)	1995-07-18	Method of treatment for muscular dystrophy
EP0255287A2 (fr)	1988-02-03	Médicament pour l'amélioration de la circulation, du métabolisme et de la fonction cérébrale
US2817623A (en)	1957-12-24	Tabernanthine, ibogaine containing analgesic compositions
EP0951907A1 (fr)	1999-10-27	Utilisation de la moxonidine en tant qu'agent stimulateur de la calogènese
EP0137514B1 (fr)	1988-09-21	Dérivés et compositions utiles dans la prévention et le traitement de l'obésité
US3988461A (en)	1976-10-26	Pharmaceutical composition for the treatment of Parkinson's disease
EP1581163A2 (fr)	2005-10-05	Methode de traitement de troubles du comportement
EP3946353A1 (fr)	2022-02-09	Composés destinés à être utilisés dans le traitement de la dyskinésie associée à adcy5
US4879298A (en)	1989-11-07	Novel method and composition